
TY  - JOUR
TI  - Poster Presentation Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 36
IS  - s1
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12266
DO  - doi:10.1111/ijlh.12266
SP  - 30
EP  - 131
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster Session Group II – Red TPS 20
JO  - Allergy
JA  - Allergy
VL  - 70
IS  - S101
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12720
DO  - doi:10.1111/all.12720
SP  - 409
EP  - 506
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts from the International Veterinary Emergency and Critical Care Symposium and the European Veterinary Emergency and Critical Care Society Annual Congress, 2010
JO  - Journal of Veterinary Emergency and Critical Care
VL  - 20
IS  - s1
SN  - 1479-3261
UR  - https://doi.org/10.1111/j.1476-4431.2010.00566.x
DO  - doi:10.1111/j.1476-4431.2010.00566.x
SP  - A1
EP  - A27
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 17
IS  - s1
SN  - 1756-1841
UR  - https://doi.org/10.1111/1756-185x.12344
DO  - doi:10.1111/1756-185x.12344
SP  - 1
EP  - 133
PY  - 2014
ER  - 

TY  - JOUR
TI  - Research Communications of the 26th ECVIM-CA Congress
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 31
IS  - 1
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.14600
DO  - doi:10.1111/jvim.14600
SP  - 186
EP  - 270
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Session 2
JO  - European Journal of Heart Failure Supplements
JA  - European Journal of Heart Failure Supplements
VL  - 10
IS  - S1
SN  - 1567-4215
UR  - https://doi.org/10.1093/eurjhf/hsr005
DO  - doi:10.1093/eurjhf/hsr005
SP  - S60
EP  - S104
PY  - 2011
ER  - 

TY  - JOUR
AU  - Kocyigit, Ismail
AU  - Eroglu, Eray
AU  - Gungor, Ozkan
TI  - Clinical problems in hemodialysis patients with autosomal dominant polycystic kidney disease
JO  - Seminars in Dialysis
JA  - Semin Dial
VL  - 31
IS  - 3
SN  - 0894-0959
UR  - https://doi.org/10.1111/sdi.12696
DO  - doi:10.1111/sdi.12696
SP  - 268
EP  - 277
PY  - 2018
AB  - Abstract Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disease characterized by massive enlargement of fluid-filled cysts in the kidney. Due to its genetic pattern, the disease differs from other CKD. ADPKD is a multi-system, progressive disorder which is frequently complicated with hypertension, cardiovascular events and cerebrovascular disease. Thus, there are many clinical problems specific to ADPKD. In this article, we reviewed these clinical problems and their management in ADPKD with hemodialysis patients.
ER  - 

AU  - Rossor, Martin
AU  - Collinge, John
AU  - Fox, Nick
AU  - Howard, Robin
AU  - Mallucci, Giovanna
AU  - Mummery, Catherine
AU  - Warren, Jason
C7  - pp. 245-288
TI  - Cognitive Impairment and Dementia
SN  - 9781405134439
UR  - https://doi.org/10.1002/9781444311709.ch7
DO  - doi:10.1002/9781444311709.ch7
SP  - 245-288
KW  - cognitive impairment and dementia
KW  - cognitive functions and clinical syndromes
KW  - paramnesias - characterized by false or distorted recall
KW  - transient global amnesia - sudden onset of severe anterograde amnesia
KW  - Fronto-temporal lobar degeneration (FTLD)
KW  - Morvan's syndrome - associated CNS involvement with severe insomnia, seizures, hyperhidrosis and encephalopathy
KW  - management of dementia
PY  - 2018
AB  - Summary This chapter contains sections titled: Introduction Epidemiology: delirium and dementia Cognitive functions and their clinical syndromes Investigation of the patient with cognitive impairment The dementias Management of dementia References
ER  - 

TY  - JOUR
TI  - 2011 ACCP Annual Meeting
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 31
IS  - 10
SN  - 9781405134439
UR  - https://doi.org/10.1592/phco.31.10.311e
DO  - doi:10.1592/phco.31.10.311e
SP  - 311e
EP  - 453e
PY  - 2011
ER  - 

TY  - JOUR
AU  - Namgoong, Sik
AU  - Jung, Suyoung
AU  - Han, Seung-Kyu
AU  - Jeong, Seong-Ho
AU  - Dhong, Eun-Sang
AU  - Kim, Woo-Kyung
TI  - Risk factors for major amputation in hospitalised diabetic foot patients
JO  - International Wound Journal
JA  - Int Wound J
VL  - 13
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1111/iwj.12526
DO  - doi:10.1111/iwj.12526
SP  - 13
EP  - 19
KW  - Diabetic foot
KW  - Major amputation
KW  - Risk factor
PY  - 2016
AB  - Abstract Diabetic foot ulcers are the main cause of non-traumatic lower extremity amputation. The objective of this study was to evaluate the risk factors for major amputation in diabetic foot patients. Eight hundred and sixty diabetic patients were admitted to the diabetic wound centre of the Korea University Guro Hospital for foot ulcers between January 2010 and December 2013. Among them, 837 patients were successfully monitored until complete healing. Ulcers in 809 patients (96·7%) healed without major amputation and those in 28 patients (3·3%) healed with major amputation. Data of 88 potential risk factors including demographics, ulcer condition, vascularity, bioburden, neurology and serology were collected from patients in the two groups and compared. Among the 88 potential risk factors, statistically significant differences between the two groups were observed in 26 risk factors. In the univariate analysis, which was carried out for these 26 risk factors, statistically significant differences were observed in 22 risk factors. In a stepwise multiple logistic analysis, six of the 22 risk factors remained statistically significant. Multivariate-adjusted odds ratios were 11·673 for ulcers penetrating into the bone, 8·683 for dialysis, 6·740 for gastrointestinal (GI) disorders, 6·158 for hind foot ulcers, 0·641 for haemoglobin levels and 1·007 for fasting blood sugar levels. The risk factors for major amputation in diabetic foot patients were bony invasions, dialysis, GI disorders, hind foot locations, low levels of haemoglobin and elevated fasting blood sugar levels.
ER  - 

TY  - JOUR
AU  - Pierre, Joseph F.
AU  - Heneghan, Aaron F.
AU  - Lawson, Christy M.
AU  - Wischmeyer, Paul E.
AU  - Kozar, Rosemary A.
AU  - Kudsk, Kenneth A.
TI  - Pharmaconutrition Review
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 37
IS  - 5S
SN  - 9781405134439
UR  - https://doi.org/10.1177/0148607113493326
DO  - doi:10.1177/0148607113493326
SP  - 51S
EP  - 65S
KW  - immunonutrition
KW  - pharmaconutrition
KW  - immune modulation
KW  - nutrition therapy
PY  - 2013
AB  - The search to improve outcomes in critically ill patients through nutrition support has steadily progressed over the past 4 decades. One current approach to this problem is the addition of specific nutrients as primary therapy to improve host defenses and improve the outcome of critically ill patients. The field is referred to as ?pharmaconutrition,? with the hope of focusing investigations on each nutrient to understand its pharmacological effects on immune and clinical outcomes. The purpose of this review is to describe some of the known physiological mechanisms of pharmaconutrients such as glutamine, arginine, ?-3 fatty acids, and selenium.
ER  - 

TY  - JOUR
TI  - Australasian College of Dermatologists Abstracts Presented at the 49th Annual Scientific Meeting 14–17 May 2016 Perth, Western Australia
JO  - Australasian Journal of Dermatology
JA  - Australas J Dermatol
VL  - 57
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1111/ajd.12480
DO  - doi:10.1111/ajd.12480
SP  - 3
EP  - 85
PY  - 2016
ER  - 

TY  - JOUR
TI  - Short papers
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s1
SN  - 9781405134439
UR  - https://doi.org/10.1002/bjs.9729
DO  - doi:10.1002/bjs.9729
SP  - 9
EP  - 118
PY  - 2015
ER  - 

TY  - JOUR
TI  - Posters
JO  - Clinical Microbiology and Infection
VL  - 16
IS  - s2
SN  - 9781405134439
UR  - https://doi.org/10.1111/j.1469-0691.2010.03239.x
DO  - doi:10.1111/j.1469-0691.2010.03239.x
SP  - S133
EP  - S634
PY  - 2010
ER  - 

TY  - JOUR
AU  - Beenakker, Karel G.M.
AU  - Duijnisveld, Bouke J.
AU  - Van Der Linden, Henrica M.J.
AU  - Visser, Cornelis P.J.
AU  - Westendorp, Rudi G.J.
AU  - Butler-Brown, Gillian
AU  - Nelissen, Rob G.H.H.
AU  - Maier, Andrea B.
TI  - Muscle characteristics in patients with chronic systemic inflammation
JO  - Muscle & Nerve
JA  - Muscle Nerve
VL  - 46
IS  - 2
SN  - 9781405134439
UR  - https://doi.org/10.1002/mus.23291
DO  - doi:10.1002/mus.23291
SP  - 204
EP  - 209
KW  - inflammation
KW  - lipofuscin
KW  - muscle fiber type
KW  - satellite cells
KW  - skeletal muscle
PY  - 2012
AB  - Abstract Introduction: Histological characteristics of age-related muscle wasting are type II muscle fiber atrophy, accumulation of oxidative stress-induced lipofuscin granules and decreased satellite cell numbers. There is increasing clinical evidence for a strong correlation between chronic systemic inflammation and age-related muscle wasting. The aim of this study was to determine the impact of chronic systemic inflammation on age-related histological muscle characteristics. Methods: As a model for chronic systemic inflammation, we included 10 patients suffering from rheumatoid arthritis (RA) and 27 control patients suffering from osteoarthritis (OA). Biopsies were taken from the vastus medialis muscle. Results: No significant differences were found in type II muscle fiber atrophy, lipofuscin accumulation, or satellite cell number in RA compared with OA patients. Conclusions: These results suggest there is no association between chronic systemic inflammation in RA and age-related muscle characteristics. Future research should focus on inflammation and satellite cell function. Muscle Nerve 46: 204?209, 2012
ER  - 

TY  - JOUR
AU  - Bulluck, Heerajnarain
AU  - Chan, Mervyn H. H.
AU  - Bryant, Jennifer A.
AU  - Chai, Ping
AU  - Chawla, Ashish
AU  - Chua, Terrance S.
AU  - Chung, Yiu-Cho
AU  - Fei, Gao
AU  - Ho, Hee H.
AU  - Ho, Andrew F. W.
AU  - Hoe, Andrew J.
AU  - Imran, Syed S.
AU  - Lee, Chi-Hang
AU  - Lim, Swee H.
AU  - Liew, Boon W.
AU  - Yun, Patrick L. Z.
AU  - Hock, Marcus O. E.
AU  - Paradies, Valeria
AU  - Roe, Matthew T.
AU  - Teo, Lynette
AU  - Wong, Aaron S.
AU  - Wong, Evelyn
AU  - Wong, Philip E.
AU  - Watson, Timothy
AU  - Chan, Mark Y.
AU  - Tan, Jack W.
AU  - Hausenloy, Derek J.
TI  - Platelet inhibition to target reperfusion injury trial: Rationale and study design
JO  - Clinical Cardiology
JA  - Clin Cardiol
VL  - 42
IS  - 1
SN  - 9781405134439
UR  - https://doi.org/10.1002/clc.23110
DO  - doi:10.1002/clc.23110
SP  - 5
EP  - 12
KW  - cangrelor
KW  - cardiovascular magnetic resonance imaging
KW  - microvascular obstruction
KW  - myocardial infarct size
KW  - primary percutaneous coronary intervention
KW  - reperfusion injury
KW  - ST-segment elevation myocardial infarction
PY  - 2019
AB  - Background In ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PPCI), current oral P2Y12 platelet inhibitors do not provide maximal platelet inhibition at the time of reperfusion. Furthermore, administration of cangrelor prior to reperfusion has been shown in pre-clinical studies to reduce myocardial infarct (MI) size. Therefore, we hypothesize that cangrelor administered prior to reperfusion in STEMI patients will reduce the incidence of microvascular obstruction (MVO) and limit MI size in STEMI patients treated with PPCI. Methods The platelet inhibition to target reperfusion injury (PITRI) trial, is a phase 2A, multi-center, double-blinded, randomized controlled trial, in which 210 STEMI patients will be randomized to receive either an intravenous (IV) bolus of cangrelor (30 ?g/kg) followed by a 120-minute infusion (4 ?g/kg/min) or matching saline placebo, initiated prior to reperfusion (NCT03102723). Results The study started in October 2017 and the anticipated end date would be July 2020. The primary end-point will be MI size quantified by cardiovascular magnetic resonance (CMR) on day 3 post-PPCI. Secondary endpoints will include markers of reperfusion, incidence of MVO, MI size, and adverse left ventricular remodeling at 6 months, and major adverse cardiac and cerebrovascular events. Summary The aim of the PITRI trial is to assess whether cangrelor administered prior to reperfusion would reduce acute MI size and MVO, as assessed by CMR.
ER  - 

TY  - JOUR
TI  - 2018 International Conference on Biotechnology and Bioengineering (ICBB2018) 24–26 October 2018, Budapest, Hungary
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 124
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1111/bcpt.13165
DO  - doi:10.1111/bcpt.13165
SP  - 3
EP  - 43
PY  - 2019
ER  - 

TY  - JOUR
TI  - 2006 Abstracts: Twenty-Eighth Annual Meeting of the American Society for Bone and Mineral Research: Pennsylvania Convention Convention Center Philadelphia, Pennsylvania, USA, September 15–19, 2006
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 21
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1002/jbmr.5650211405
DO  - doi:10.1002/jbmr.5650211405
SP  - S152
EP  - S201
PY  - 2006
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 24
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1111/ene.13366
DO  - doi:10.1111/ene.13366
SP  - 19
EP  - 122
PY  - 2017
ER  - 

TY  - JOUR
TI  - Mechanisms of Injury
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
SN  - 9781405134439
UR  - https://doi.org/10.1002/hep.26846
DO  - doi:10.1002/hep.26846
SP  - 447A
EP  - 455A
PY  - 2013
ER  - 
